Livzon's internal controls strong, allocates $137m for shareholder returns

Livzon Pharmaceutical Group [SZSE:000513] has declared its financial reporting internal controls effective as of December 31, 2024, following an audit by its accounting firm. A newly issued summary details a plan approved by the Board, set at a payout ratio of around 88%, for shareholders to receive a cash dividend of RMB 1.10 per 10 shares, contingent on approval from shareholders, together with the buyback of A and H shares. Cash dividends are expected to total ¥984.1 million. Stock repurchases totaled around ¥831 million. This combined return, approximately $137 million USD, underscores the company's commitment to shareholder value.